Idenix Pharmaceuticals Inc., a U.S. drugmaker that stopped development of two hepatitis C therapies this year, plunged the most in almost three years after regulators asked for more safety data on another experimental treatment.
Affymax Inc. fell 69 percent, the most ever in Nasdaq trading, after the company released results showing greater heart risks among some kidney patients taking its investigational anemia drug Hematide than among users of Amgen Inc. ’s Aranesp.
Amgen Inc. may introduce its first dividend next month, rewarding investors whose stock in the world’s largest biotechnology company has fallen 33 percent since 2006, even as its cash hoard grew to $17.4 billion.
Shares of the following companies are having unusual moves in U.S. trading. U.S. exchanges were closed yesterday for Memorial Day. Stock symbols are in parentheses, and prices are as of 10:50 a.m. in New York.
Biogen Idec Inc., the world’s largest maker of multiple sclerosis treatments, will name George A. Scangos chief executive officer as early as today, according to a person familiar with the hiring process.
Celgene Corp. ’s best-selling cancer pill Revlimid helped prevent relapses of multiple myeloma following bone marrow transplant, a standard procedure used to treat the blood malignancy, a study showed.